Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DAVD0 HER2-CAR
- Development stage
- Preclinical
- Lead developer
- NKGen Biotech, Inc.
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
DAVD0 HER2-CAR is an investigational allogeneic chimeric antigen receptor (CAR)-engineered natural killer (NK) cell therapy being developed by NKGen Biotech. The therapy utilizes off-the-shelf NK cells modified to express a CAR targeting the Human Epidermal Growth Factor Receptor 2 (HER2). This approach aims to redirect the innate cytotoxic activity of NK cells specifically toward HER2-overexpressing tumor cells, which are prevalent in various solid malignancies including breast, gastric, and lung cancers. By using an allogeneic platform, DAVD0 is designed to be an 'off-the-shelf' product, potentially overcoming the logistical and scalability challenges associated with autologous cell therapies.
- Other names
- HER2-CAR-NKHER-2-CAR-NKHER 2-CAR-NKallogeneic HER2-CAR-NK cell therapy
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on DAVD0 HER2-CAR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DAVD0 HER2-CAR.